
當(dāng)前位置: 首頁(yè) - 產(chǎn)品目錄 - 小分子抑制劑

LY2109761 (LY-2109761)
貨號(hào) | ITB1006 | 售價(jià)(元) | 2889 |
規(guī)格 | 2mg | CAS號(hào) | 700874-71-1 |
- 產(chǎn)品簡(jiǎn)介
- 相關(guān)產(chǎn)品
貨號(hào)
名稱(chēng)
規(guī)格
價(jià)格
ITB1006-0002MG
LY2109761
2 mg
2889
ITB1006-0005MG
LY2109761
5 mg
4911
ITB1006-0010MG
LY2109761
10 mg
6365
產(chǎn)品簡(jiǎn)介:
LY2109761是一種小分子抑制劑,選擇性靶向I型和II型TGF-β受體((TβRI/II)),Ki分別為38 nM和300nM[1]。它在TβRI酶法測(cè)定中給出69 nM的IC50值[2]。晶體結(jié)構(gòu)顯示LY2109761與TGF-β R1激酶結(jié)構(gòu)域的ATP結(jié)合位點(diǎn)結(jié)合[2]。據(jù)報(bào)道,其他激酶的抑制活性較弱,包括Lck、Sapk2α、MKK6、Fyn和JNK 3(20M時(shí)抑制率為18–89%)[2]。
LY2109761在臨床前研究中顯示出潛在的抗腫瘤活性。TGF-β信號(hào)通路的異常與多種惡性腫瘤相關(guān)。LY2109761抑制胰腺癌細(xì)胞的增殖、遷移和侵襲,并誘導(dǎo)其凋亡[1]。當(dāng)與吉西他濱聯(lián)合使用時(shí),它可以抑制轉(zhuǎn)移性胰腺癌小鼠模型中的腫瘤生長(zhǎng)和轉(zhuǎn)移[1]。它還抑制了TGF-β1在骨髓-單核細(xì)胞白血病細(xì)胞中的抗凋亡作用[3]。GBM細(xì)胞系和原位顱內(nèi)模型的結(jié)果表明,LY2109761增加了放射敏感性,并延長(zhǎng)了膠質(zhì)母細(xì)胞瘤的生存期[4]。此外,LY2109761減少了小鼠模型中輻射誘導(dǎo)的肺炎和肺纖維化[5]。
產(chǎn)品性質(zhì):
Cas No.:700874-71-1
化學(xué)名: 4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine
Canonical SMILES:C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6
分子式:C26H27N5O2
分子量:441.52
溶解度:≥ 22.1mg/mL in DMSO
儲(chǔ)存條件:Store at -20°C
注意事項(xiàng):
為了您的安全和健康,請(qǐng)穿實(shí)驗(yàn)服并戴一次性手套操作。
References:
[1] Melisi D, Ishiyama S, Sclabas GM et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008; 7: 829-840.
[2] [2]Li HY, McMillen WT, Heap CR et al. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. J Med Chem 2008; 51: 2302-2306.
[3] Xu Y, Tabe Y, Jin L et al. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol 2008; 142: 192-201.
[4] Zhang M, Kleber S, Rohrich M et al. Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011; 71: 7155-7167.
[5]Flechsig P, Dadrich M, Bickelhaupt S et al. LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-beta and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res 2012; 18: 3616-3627.
- 上一頁(yè): ITD-1
- 下一頁(yè): LY364947 (LY-364947, HTS 466284)